Eiger BioPharmaceuticals’ (NASDAQ:EIGR) ubenimex for lymphedema triggered mostly optimistic expert expectations for the Phase II primary outcome. They pointed to positive clinical results of a molecule with a similar MOA and preclinical data with ubenimex that supports that mechanism.
Yet, a lymphedema expert expressed scepticism that the drug could reverse disease progression and its manifestations. The primary endpoint, even if successful, might have little clinical meaning to patients, she added, though other experts said the measure was rational. Secondary endpoints were deemed appropriate, with one expert noting they could have also sufficed as coprimary measures.
The Phase II (NCT02700529) is expected to read-out in 3Q18. With the discontinuation of ubenimex in pulmonary arterial hypertension earlier this year, attention is focused on lymphedema, an analyst report noted, predicting peak sales of around USD 200m. Eiger’s market cap is USD 197m.